Supernus Pharmaceuticals ist ein auf die Biopharmazie spezialisiertes Unternehmen, das sich auf die Entwicklung und Vermarktung von Produkten zur Behandlung…
Supernus Pharmaceuticals ist ein biopharmazeutisches Unternehmen aus den USA, das sich auf die Entwicklung und Kommerzialisierung von Produkten zur Behandlung…
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the…
…
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and…
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.…
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage…
Investors need to pay close attention to Supernus Pharmaceuticals (SUPN) stock based on the movements in the options market lately…
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the…
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
…
Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the…
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
…
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the…
ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster,…
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
…
ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus Pharmaceuticals exec sells over $500k in stock…
Supernus Pharmaceuticals exec sells $436k in stock…
Supernus Pharmaceuticals executive sells over $2.1m in stock…
Supernus Pharmaceuticals executive trades company stock…
…